Gamma-secretase · PROTEIN COMPLEX · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13Gamma-secretase shows approved-linked disease relevance led by Gastrointestinal desmoid tumor. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt Q96BI3. Start with Gastrointestinal desmoid tumor, then reuse UniProt Q96BI3 as the stable protein anchor across project notes and exports.
Start with Gastrointestinal desmoid tumor, then reuse UniProt Q96BI3 as the stable protein anchor across project notes and exports.
Gamma-secretase shows approved-linked disease relevance led by Gastrointestinal desmoid tumor. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with Gastrointestinal desmoid tumor because it currently carries approved-linked support. Linked drugs include NIROGACESTAT HYDROBROMIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyGamma-secretase subunit APH-1A
Review this target as Gamma-secretase, mapped to UniProt Q96BI3. ChEMBL maps the protein component as Gamma-secretase subunit APH-1A. Sequence length is 265 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Gamma-secretase as ChEMBL target CHEMBL2094135, mapped to UniProt Q96BI3. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Gamma-secretase is the right protein anchor across sources, using UniProt Q96BI3 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why Gastrointestinal desmoid tumor is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Gamma-secretase |
| Target Type | PROTEIN COMPLEX |
| Organism | Homo sapiens |
| UniProt | Q96BI3 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Gamma-secretase subunit APH-1A |
| UniProt Accession | Q96BI3 |
| Component Type | Protein |
| Sequence Length | 265 aa |
Gamma-secretase subunit APH-1A
Review this target as Gamma-secretase, mapped to UniProt Q96BI3. ChEMBL maps the protein component as Gamma-secretase subunit APH-1A. Sequence length is 265 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Gamma-secretase shows approved-linked disease relevance led by Gastrointestinal desmoid tumor. 5 more disease programs remain visible in the same review block.
Start review with Gastrointestinal desmoid tumor because it currently carries approved-linked support. Linked drugs include NIROGACESTAT HYDROBROMIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL4456488 | 10.99 | EC50 | 0.0103 | Preclinical |
| CHEMBL4443026 | 10.94 | EC50 | 0.0114 | Preclinical |
| CHEMBL4525398 | 10.93 | EC50 | 0.0117 | Preclinical |
| CHEMBL4547187 | 10.89 | EC50 | 0.013 | Preclinical |
| CHEMBL4535601 | 10.86 | EC50 | 0.0139 | Preclinical |
| CHEMBL392113 | 10.82 | IC50 | 0.015 | Preclinical |
| CHEMBL235659 | 10.7 | IC50 | 0.02 | Preclinical |
| CHEMBL235869 | 10.62 | IC50 | 0.024 | Preclinical |
| CHEMBL468083 | 10.52 | IC50 | 0.03 | Preclinical |
| CHEMBL209888 | 10.4 | IC50 | 0.04 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 377 | 1,957 | 7.0 |
| protein complex format | 75 | 358 | 7.2 |
| cell membrane format | 3 | 6 | 7.3 |
| assay format | 2 | 2 | 6.9 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 10 | 122 | 6.6 |
| assay format | 2 | 0 | — |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 4 | 0 | — |
| protein complex format | 2 | 2 | 7.5 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 1 | 0 | — |